List of Excipients in API orforglipron
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing orforglipron
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| Eli Lilly and Company | FOUNDAYO | orforglipron | 0002-4178 | CELLULOSE, MICROCRYSTALLINE | |
| Eli Lilly and Company | FOUNDAYO | orforglipron | 0002-4178 | COPOVIDONE K25-31 | |
| Eli Lilly and Company | FOUNDAYO | orforglipron | 0002-4178 | CROSPOVIDONE | |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for orforglipron
Excipient focus: CELLULOSE, MICROCRYSTALLINE
orforglipron drug variants containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| Eli Lilly and Company | orforglipron | 0002-4178 |
| >Company | >Ingredient | >NDC |
orforglipron drug variants not containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: COPOVIDONE K25-31
orforglipron drug variants containing COPOVIDONE K25-31
| Company | Ingredient | NDC |
|---|---|---|
| Eli Lilly and Company | orforglipron | 0002-4178 |
| >Company | >Ingredient | >NDC |
orforglipron drug variants not containing COPOVIDONE K25-31
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CROSPOVIDONE
orforglipron drug variants containing CROSPOVIDONE
| Company | Ingredient | NDC |
|---|---|---|
| Eli Lilly and Company | orforglipron | 0002-4178 |
| >Company | >Ingredient | >NDC |
orforglipron drug variants not containing CROSPOVIDONE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE RED
orforglipron drug variants containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| Eli Lilly and Company | orforglipron | 0002-4178 |
| >Company | >Ingredient | >NDC |
orforglipron drug variants not containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE YELLOW
orforglipron drug variants containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| Eli Lilly and Company | orforglipron | 0002-4178 |
| >Company | >Ingredient | >NDC |
orforglipron drug variants not containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MAGNESIUM STEARATE
orforglipron drug variants containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| Eli Lilly and Company | orforglipron | 0002-4178 |
| >Company | >Ingredient | >NDC |
orforglipron drug variants not containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYETHYLENE GLYCOL 4000
orforglipron drug variants containing POLYETHYLENE GLYCOL 4000
| Company | Ingredient | NDC |
|---|---|---|
| Eli Lilly and Company | orforglipron | 0002-4178 |
| >Company | >Ingredient | >NDC |
orforglipron drug variants not containing POLYETHYLENE GLYCOL 4000
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYVINYL ALCOHOL
orforglipron drug variants containing POLYVINYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| Eli Lilly and Company | orforglipron | 0002-4178 |
| >Company | >Ingredient | >NDC |
orforglipron drug variants not containing POLYVINYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM CARBONATE
orforglipron drug variants containing SODIUM CARBONATE
| Company | Ingredient | NDC |
|---|---|---|
| Eli Lilly and Company | orforglipron | 0002-4178 |
| >Company | >Ingredient | >NDC |
orforglipron drug variants not containing SODIUM CARBONATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TALC
orforglipron drug variants containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| Eli Lilly and Company | orforglipron | 0002-4178 |
| >Company | >Ingredient | >NDC |
orforglipron drug variants not containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
orforglipron drug variants containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Eli Lilly and Company | orforglipron | 0002-4178 |
| >Company | >Ingredient | >NDC |
orforglipron drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch